BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.
Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise. Our extensive library of RenMice®-derived, fully human antibodies could serve as an important resource for Gilead to accelerate development of multiple novel antibody-based therapeutics to treat a variety of diseases. We are committed to supporting Gilead as well as our other partners in their drug development endeavors to benefit patients.”
About Biocytogen’s Fully Human Antibody Library
Biocytogen’s antibody library was generated using a series of proprietary RenMice® platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMabTM mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties. Second-generation RenLite® and RenNano® models, which generate common light chain antibodies and heavy-chain-only antibodies, respectively, further facilitate generation of fully human multi-specific antibodies or nanobodies. RenMice have also been engineered to lack specific drug targets; these targeted knockout platforms can generate antibodies with enhanced sequence and epitope diversity. This platform increases the likelihood of discovering novel species cross-reactive antibodies to facilitate downstream in vivo screening and identification of differentiated antibody candidates. A library featuring available antibody sequences along with characterization data is ready for immediate evaluation and partnership opportunities.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220445787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celonis Research Unveils: 89% of Business Leaders say AI Without Process Intelligence Fails to Deliver Expected Results5.2.2025 10:00:00 CET | Press release
The vast majority of decision makers surveyed (89%) said AI needs to have the context of how their business runs to deliver the expected results.81% of respondents said their companies plan to use AI specifically to improve business processes in the next 12 months.The majority (58%) of leaders worry that process shortcomings may limit AI’s contribution to their business. Celonis, the global leader in Process Mining and Process Intelligence, today released survey findings that demonstrate widespread recognition that AI requires Process Intelligence to be effective and relevant for the business. With Celonis Process Intelligence, AI gains the context it needs to understand how a business runs and how to make it run better. The 2025 Process Optimization Report shows that the vast majority of enterprise leaders (89%) say it’s crucial that AI has the context of how their business runs if it is going to deliver meaningful results and increase operational efficiency. The majority (58%) worry
Infobip Recognized as a Worldwide CPaaS Leader by IDC MarketScape for the Third Time5.2.2025 10:00:00 CET | Press release
Global cloud communications platform Infobip has been named as a Leader in the IDC MarketScape: Worldwide Communications Platform as a Service (CPaaS) 2025 Vendor Assessment. This is the third time that Infobip has been named a Leader in this report. According to the report, “Infobip is a key player in the CPaaS market with a global footprint and strong capabilities underpinned by its broad portfolio for enterprises as well as a carrier-grade service offering.” Courtney Munroe, Research Vice President, Worldwide Telecommunications Research at IDC, said:“Infobip has an agile organization structure and appetite for innovation to meet evolving enterprise requirements that stimulates continued expansion of its capabilities and global presence. The firm’s strong breadth and depth of services has enabled it to grow rapidly while maintaining a strong financial position.” Silvio Kutić, CEO at Infobip, said: “Over the last year, Infobip has continued to invest in innovative new services. For in
FoodChain ID and &Wider Announce Partnership for Responsible and Transparent Supply Chains That Protect Workers and Brands5.2.2025 10:00:00 CET | Press release
FoodChain ID, a provider of certification services and technology for the agriculture and food industry, and &Wider, a due diligence data company measuring worker engagement for responsible sourcing, announce their partnership for risk-based monitoring and auditing of worker conditions and engagement. The new service meets the demand from global brands to monitor and mitigate potential worker issues within their supply chains, as well as the requirements for transparent actions and reporting under the European Union’s (EU) Corporate Sustainability Due Diligence Directive (CSDDD) and Corporate Sustainability Reporting Directive (CSRD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250205893945/en/ FoodChain ID and &Wider have announced a partnership for risk-based monitoring and auditing of food industry worker conditions to protect workers and food brands. (Photo: Business Wire) The CSDDD created an obligation for due dilig
Alipay Records Surge of China Inbound and Outbound Travel Spending During the 2025 Chinese New Year5.2.2025 07:59:00 CET | Press release
The number of Alipay transactions made by outbound Chinese travelers across the 90 million-strong Alipay+ global merchants network increased by 30% y-o-y. The top destinations for Chinese travelers are Singapore, Japan, Malaysia, Hong Kong SAR, and South Korea, showing the highest growth rate in total Alipay spending.China inbound travel spending via Alipay surged by 150% y-o-y in the first five days of the Chinese New Year (CNY) holiday. The number of inbound travelers using their 13 home e-wallets supported by the Alipay+ solution nearly doubled y-o-y during the first four days of the holiday.Alipay’s flagship Fortune Cards Campaign drew 600 million participants this year, reaching a cumulative of one billion users in the past decade since its launch in 2016. During the 2025 Chinese New Year, Alipay recorded a significant increase in China’s outbound and inbound travel spending. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home
Hitachi Establishes Its Fourth Corporate Venture Capital Fund to Capture Technology Turning Points and Future Growth Opportunities5.2.2025 07:00:00 CET | Press release
Total Assets Under Management (AUM) Reaches 1 Billion USD, Contributing to Sustainable Growth with a World-Class Investment Scale Hitachi, Ltd. (TSE: 6501, "Hitachi") today announced the establishment of the fourth fund of the corporate venture capital (hereinafter referred to as "CVC") fund"HV Fund" with a purpose to identify startups with the potential to create or disrupt large attractive markets, anticipate the next technological and social turning points, and generate future growth opportunities. The fourth fund will have a size of 400 million USD, which is the largest CVC fund managed by Hitachi to date. The fund will make strategic investments in startups with cutting-edge digital technologies such as data centers, distributed energy systems, future of work and industrial AI, as well as startups in new frontiers including bio, quantum, nuclear fusion, life science, space and adjacent technologies. With the establishment of the fourth fund, Hitachi's investment in CVC will reach
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom